This GLP-1 agonist binds to the receptor of the endogenous intestinal hormone GLP-1 to enhance insulin secretion and inhibit glucagon production, thereby inhibiting the development of fatty liver in patients with T2DM (Wang et al., 2017; Moreira et al., 2018). Here, INS is linked to type 2 diabetes mellitus.